Zimmer expands ASC footprint with Getinge distribution deal

Editor's Note

Zimmer Biomet is taking a strategic step to dominate the ambulatory surgery center (ASC) market by partnering with Getinge to distribute surgical and infection control products, broadening its offering beyond implants and robotics, MedTech Dive July 14 reports. The partnership would provide ASCs with a single-source solution for implants, robotics, and OR infrastructure.

Announced on July 10 by both companies, the deal enables Zimmer to distribute Getinge’s OR capital products and infection control and surgical portfolio under its ZBX ASC Solutions platform. The deal reportedly allows Zimmer to offer a more comprehensive product suite—including surgical equipment, lighting, and sterilization systems—alongside its core orthopedic implants and surgical robots.

Per the article, this move reflects Zimmer’s growing focus on ASCs, which are gaining traction due to increased Medicare reimbursement. Since Medicare began covering total knee replacements in 2020 and hip replacements in 2021, the number of Medicare-certified ASCs has climbed to nearly 6,500, up from just over 6,000 in late 2022. The outlet reports that Zimmer has seen ASC-related sales jump significantly, with CEO Ivan Tornos stating that ASCs now account for around 20% of US sales, compared to just 2% to 4% pre-pandemic. The company projects that ASCs could comprise 40% to 60% of sales within 5 years.

Jehanzeb Noor, Zimmer’s chief strategy, innovation, and business development officer, noted in the article that as orthopedic procedures shift away from hospitals, ASCs are under pressure to improve efficiency, safety, and outcomes. Aligning with Getinge, Noor said, helps Zimmer deliver on those goals by equipping ASCs with a broader range of integrated solutions.

This partnership follows Zimmer’s $1.1 billion acquisition of foot and ankle implant company Paragon 28, announced earlier this year. Speaking at a Goldman Sachs event in June, Tornos emphasized the Paragon 28 acquisition will enhance Zimmer’s ASC market position through cross-selling opportunities in trauma and biologics, and hinted at additional deals on the horizon.